Table 3.
Complication Frequencies.
| Complication | Percent affected (95% CI) | I2 (95% CI) | Cochran’s Q P value |
|---|---|---|---|
| Patients with at least 1 treatment-related AE | 94% (86, 97) | 84% (71, 91) | <.001 |
| Minor AE | |||
| Peripheral edema | 64% (49, 76) | 95% (92, 97) | <.001 |
| Contusion | 51% (34, 68) | 94% (89, 97) | <.001 |
| Pain in extremity | 53% (36, 70) | 96% (93, 97) | <.001 |
| Ecchymosis | 41% (11, 80) | 99% (98, 99) | <.001 |
| Injection site pain | 33% (20, 50) | 97% (95, 98) | <.001 |
| Tenderness | 28% (16, 44) | 88% (65, 96) | <.001 |
| Skin laceration | 27% (21, 33) | 86% (79, 91) | .0013 |
| Injection site swelling | 24% (7.7, 54) | 99% (98, 99) | <.001 |
| Injection site hematoma | 23% (6.3, 58) | 97% (96, 98) | <.001 |
| Pruritus | 20% (13, 28) | 90% (81, 94) | <.001 |
| Injection site hemorrhage | 19% (8.4, 37) | 96% (94, 98) | <.001 |
| Lymphadenopathy | 15% (11, 20) | 83% (72, 90) | <.001 |
| Blood blister | 11% (5.9, 20) | 91% (88, 96) | <.001 |
| Axillary pain | 6.2% (4.5, 8.5) | 25% (0, 70) | .2523 |
| Injection site vesicles | 2.6% (1.1, 5.6) | — | .3416 |
| Major nonsurgical AE | |||
| Nonrupture tendon injury | 0.62% (0.32, 1.21) | 0% (0, 15) | .906 |
| Anaphylaxis | 0.61% (0.31, 1.19) | 0% (0, 17.1) | .896 |
| Major surgical AE | |||
| Tendon and pulley rupture | 0.98% (0.58, 1.65) | 0% (0, 44.4) | .612 |
Note. CI = confidence interval; AE = adverse events.